Dossier assessment
Ceritinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Ceritinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Ceritinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
First-line treatment of adult patients with advanced ALK-positive NSCLC
Added benefit not proven due to the lack of similarity of the indirectly compared studies
Additional information
Federal Joint Committee (G-BA)
2019-02-01 A G-BA decision was published.
Project details
- Project no.
- A17-32
- Commission
- Commission awarded on 20.07.2017 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Ceritinib (lung cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Ceritinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed